Clinical trials: Inflammatory
Lupus Erythematosus, Systemic
Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)
The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with mild to moderately active Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT05203419
- Testing
- MHS552
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Colitis, Ulcerative
To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis
To demonstrate non-inferiority in efficacy of FE 999315 to mesalazine in patients with mild to moderate active ulcerative colitis after 8 weeks of treatment.
- Trial name
- NCT03412682
- Testing
- Budesonide (6 mg), Budesonide (9 mg), Mesalazine (3,600 mg)
- Where
- 72 sites in Japan
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
IBD
A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease
Treatment with iron isomaltoside and ferric carboxymaltose in subjects with iron deficiency anaemia due to inflammatory bowel disease and comparison of the incidence of hypophosphatemia
- Trial name
- NCT03466983
- Testing
- Iron Isomaltoside, Ferric Carboxymaltose
- Where
- Denmark
- Volunteers
- 97 people
- Sponsor
- Pharmacosmos A/S
Low Gelsolin, Trauma
Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels
This study is designed to assess the pharmacokinetics and safety of an infusion of a single dose of recombinant plasma gelsolin (rhu-pGelsolin) when given to patients admitted to the Intensive Care Unit with documented low levels…
- Conditions
- Low Gelsolin, Trauma, Infection, Burns
- Trial name
- NCT00671307
- Testing
- rhu-pGelsolin
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Critical Biologics Corporation
Colitis, Ulcerative
A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HX15001 injection combined with Etrasimod tablets in participants with moderately to severely active ulcerative…
- Trial name
- NCT07768254
- Testing
- Biological: HX15001
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Crohn Disease
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with…
- Trial name
- NCT07310095
- Testing
- Guselkumab (GUS)
- Where
- 5 sites in China
- Volunteers
- 78 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Inflammatory Bowel Diseases, IBD
Multiple Dose Ethnobridging PK Study in Healthy Subjects
A Phase 1, double blind, placebo controlled, 4 cohort, multiple dose study in healthy adult Japanese and Caucasian subjects.
- Trial name
- NCT03750565
- Testing
- TD-1473 - Dose A, TD-1473 - Dose B, TD-1473 - Dose C
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis).
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
- Trial name
- ASCEND-IBD (NCT07113522)
- Testing
- MT-501, MT-201
- Where
- 66 sites in United States, Canada and 3 more
- Volunteers
- 140 people
- Sponsor
- Mirador Therapeutics, Inc.
Inflammatory Bowel Disease
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
The primary objective of this study is to evaluate the testicular safety of filgotinib in adult males with moderately to severely active inflammatory bowel disease (IBD).
- Trial name
- MANTA (NCT03201445)
- Testing
- Filgotinib, Standard of Care
- Where
- 56 sites in United States, Australia and 9 more
- Volunteers
- 139 people
- Sponsor
- Lakefront Biotherapeutics NV
Spondylitis, Ankylosing
An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement
The purpose of this observational (a study that follows participants forward in time) study is to compare the functional improvement of hip joint using Harris hip score between 2 treatment groups (infliximab and conventional…
- Trial name
- RECOVERY (NCT02293681)
- Testing
- Infliximab, NSAIDs, DMARDs
- Where
- 6 sites in China
- Volunteers
- 76 people
- Sponsor
- Janssen Research & Development, LLC
Constipation
To Evaluate the Safety and Efficacy of Pediococcus Acidilactici PA53 in Relieving Constipation in Adults
To study the improvement of constipation symptoms, quality of life and mental state, intestinal function, intestinal hormones, inflammation and immunity, and intestinal flora of constipation subjects after 8-week intervention…
- Trial name
- NCT06761443
- Testing
- Probiotic, Maltodextrin
- Where
- China
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Health, Subjective, Inflammatory Response
Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults
The goal of this observational study is to provide exploratory research into the in vivo physiological and psychological effects, if any, of cannabigerol (CBG) in healthy human adults age 21 or over.
- Conditions
- Health, Subjective, Inflammatory Response, Adverse Effect, Side Effect
- Trial name
- NCT05743985
- Testing
- Cannabigerol
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Formula30A LLC
Chronic Inflammatory Small Bowel Disease
GI Fluids Collection for an Ex-Vivo Development of Ingestible Capsule Devices With Real Time Biosensors
Up to 500 subjects undergoing standard endoscopy / pouchoscopy, or having ileostomy or colostomy bags or having an ileal pouch and who meet the eligibility criteria will be enrolled to this study during up to three years at up to…
- Trial name
- CLARINET (NCT02797535)
- Testing
- Endoscopy procedures
- Where
- 2 sites in Israel
- Volunteers
- 66 people
- Sponsor
- Medtronic - MITG
Ulcerative Colitis
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- NCT06257875
- Testing
- Lutikizumab, Adalimumab
- Where
- 191 sites in United States, Australia and 28 more
- Volunteers
- 156 people
- Sponsor
- AbbVie
Crohn's Disease
Laquinimod Phase IIa Study in Active Crohn's Disease
The study aims to evaluate the safety and clinical effect of daily oral treatment of Laquinimod capsules in active moderate to severe Crohn's disease.
- Trial name
- NCT00737932
- Testing
- Laquinimod
- Where
- 34 sites in Belgium, France and 7 more
- Volunteers
- 180 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Crohn's Disease
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
The study consists of 4 sub-studies, as follows: Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in participants with…
- Trial name
- FORTIFY (NCT03105102)
- Testing
- Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI)
- Where
- 496 sites in United States, Argentina and 45 more
- Volunteers
- 1,336 people
- Sponsor
- AbbVie
Pain, Inflammatory
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)
This study is the first administration of GSK3858279 in humans and will be conducted in two parts: Part A will consist of a single ascending dose escalation design to evaluate safety, tolerability, PK, TE and immunogenicity of…
- Trial name
- NCT03485365
- Testing
- GSK3858279 IV, GSK3858279 SC
- Where
- 5 sites in Germany, Poland and 1 more
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Crohn's Disease
Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
The goal of this study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease who have been initially treated with infliximab and either lost response or discontinued its use as a…
- Trial name
- NCT00105300
- Testing
- Adalimumab
- Where
- 56 sites in United States, Belgium and 2 more
- Volunteers
- 300 people
- Sponsor
- Abbott
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- NURTURE 1 (NCT01350804)
- Testing
- AIN457, Abatacept
- Where
- 117 sites in United States, Brazil and 13 more
- Volunteers
- 551 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Sjogren's Syndrome
Cell Surface Marker Expression in Autoimmune Diseases
This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) systemic sclerosis, (e) Crohn's…
- Conditions
- Systemic Lupus Erythematosus, Sjogren's Syndrome, Multiple Sclerosis, Systemic Sclerosis
- Trial name
- CASCADE (NCT03757065)
- Where
- 2 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Alpine Immune Sciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.